Catawba forms strategic partnership with PharmaLegacy

Catawba Research has partnered with Shanghai-headquartered contractor PharmaLegacy Laboratories, citing access to China’s research services market as a prompt for the deal.

In addition to increasing its APAC presence, Catawba said the accord will streamline drug development for customers by offering a single source for both preclinical and clinical trial services. Financial details of the partnership were not disclosed.

CEO Andy Silverman said, “We are thrilled to partner with PharmaLegacy. Their depth of expertise in preclinical research aligns perfectly with Catawba’s commitment to delivering high-quality, efficient clinical trial management.

“This collaboration allows us to offer end-to-end solutions for our clients, accelerating the drug development process while maintaining the highest standards of scientific integrity,” he added.

This was echoed by PharmaLegacy chief Jeff Duan, who said, “We believe that by combining our capabilities, we can offer our clients a truly comprehensive research experience. Together, we can help to bring new therapies to market to benefit patients more effectively and efficiently.”

Catawba Research is headquartered in Charlotte, North Carolina, and Mumbai, India, which, the firm says, allows it to bridge the gap between Western and Eastern markets, and facilitates access to diverse patient populations.

Acquisition

The deal comes a few months after PharmaLegacy acquired San Diego, California-based preclinical contract research organization (CRO) BTS Research.

At the time the Shanghai firm said BTS would expand its service offering and build its presence in San Diego, which it described as a “significant global R&D hub.”

Duan said, “This acquisition will allow us to better serve clients across the US and North America while increasing our study capacity and providing more flexibility for all our clients. As such, it is a crucial step to becoming an industry-leading preclinical CRO.”

DepositPhotos/alphaspirit